The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2024 | Long-term results of the Phase II REVIVE study evaluating rusfertide in patients with PV
Kristen Pettit, MD, University of Michigan, Ann Arbor, MI, presents the updated long-term results of the Phase II REVIVE study (NCT04057040), which evaluated rusfertide in patients with polycythemia vera (PV) who are phlebotomy dependent. Long-term data demonstrate that the initial hematocrit responses and decrease in phlebotomy needs are maintained, with no new safety signals reported. The agent is now being studied further in the Phase III VERIFY study (NCT05210790). This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Advisory Boards: AbbVie, Protagonist, GSK, Sobi.
